Reuters logo
5 months ago
BRIEF-Shire reports positive results in phase 1b study of skin swelling drug Lanadelumab
February 23, 2017 / 9:32 AM / 5 months ago

BRIEF-Shire reports positive results in phase 1b study of skin swelling drug Lanadelumab

1 Min Read

Feb 23 (Reuters) - Shire Plc:

* Results served as basis for ongoing phase 3 trial

* No serious adverse events or discontinuations due to adverse events were observed at all doses studied

* Pre-Specified efficacy analyses in patients with at least 2 attacks in 3 months showed reduced rate of attacks by between 88-100 percent for dosage range versus placebo

* All subjects were attack-free in 300 mg group and 82 pct were attack-free in 400 mg group versus 27 pct in placebo group Source text for Eikon: Further company coverage: (Bengaluru Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below